前沿论文｜CELL INTELLIGENCE

Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.

PubMed 2025/11/29 发表CytotherapyQ1 · IF 4.5（JCR 2025）

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

PubMed 2025/08/01 发表Blood Cell Ther

该病例凸显了 epcoritamab 联合减瘤治疗用于治疗 CAR-T 难治性 CD19 阴性 DLBCL 的潜力。

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.

PubMed 2025/06/10 发表Proc Natl Acad Sci U S AQ1 · IF 9.5（JCR 2025）

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

PubMed 2025/05/06 发表Cancer Biol MedQ1 · IF 12.4（JCR 2025）

Contemporary management of diffuse large B-cell lymphoma in Japan.

PubMed 2025/04/08 发表Expert Rev Anticancer TherQ3 · IF 3（JCR 2025）

由专家或通过会诊网络对 DLBCL 进行准确的病理诊断至关重要，而一种新兴的基因组检测将有助于未来的精准诊疗方法。

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.

PubMed 2024/10/22 发表Blood AdvQ1 · IF 7.7（JCR 2025）

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

PubMed 2024/03/29 发表Blood Cell Ther

CAR-T Cell Therapy for T-Cell Malignancies.

PubMed 2024/03/01 发表Mediterr J Hematol Infect DisQ3 · IF 2.3（JCR 2025）

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.

PubMed 2023/07/28 发表Mol Ther Oncolytics

Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.

PubMed 2022/08/01 发表Curr ProtocQ3 · IF 2.5（JCR 2025）

前沿论文 10